Results from a small study suggest that melanomas in CDKN2A carriers may have better response rates to immunotherapy compared to non-carriers.
Read the article to learn more!
https://pubmed.ncbi.nlm.nih.gov/30291219/
Reference: Helgadottir et al. J Med Genet. 2020 May;57(5): 316-321. PMID: 30291219.